- Open Access
Roundtable discussion: how the World Hepatitis Summit 2015 strengthened stakeholders’ efforts to combat viral hepatitis
© The Author(s) 2016
- Received: 14 June 2016
- Accepted: 14 September 2016
- Published: 7 October 2016
The inaugural World Hepatitis Summit was jointly convened by the World Health Organization (WHO) and the World Hepatitis Alliance and hosted by the Scottish Government and supported by Glasgow Caledonian University and Health Protection Scotland in September 2015. The three day event convened a broad range of stakeholders to meet and share ideas, experience and best practice in addressing the many facets of viral hepatitis prevention, diagnosis and treatment.
With the next World Hepatitis Summit scheduled to take place from 1 to 3 November 2017, the World Hepatitis Alliance asked Hepatology, Medicine and Policy to commission a roundtable discussion article in order to encourage reflection on how the 2015 Summit was significant for stakeholders’ efforts and why it is important to keep the momentum going ahead of the World Hepatitis Summit 2017 and in the light of the newly adopted first-ever Global Health Sector Strategy on Viral Hepatitis.
- Civil Society
- Viral Hepatitis
- Health Protection
- Patient Organization
Charles Gore, President of the World Hepatitis Alliance
The inaugural World Hepatitis Summit was jointly convened by the World Health Organization (WHO) and the World Hepatitis Alliance (WHA) and hosted by the Scottish Government and supported by Glasgow Caledonian University and Health Protection Scotland in September 2015. It was the first opportunity for a broad range of policy-makers and patients to come together to discuss the global response to viral hepatitis.
The Glasgow Declaration on Viral Hepatitis
Because there are 400 million people living with hepatitis B or hepatitis C infection with no country/region unaffected,
Because there is a lack of global awareness and most persons with hepatitis remain undiagnosed,
Because 1.4 million people die every year from complications of viral hepatitis yet most of these deaths can be prevented,
Because there are highly effective measures to prevent new hepatitis B and C infections and highly effective treatments that can suppress hepatitis B virus replication and cure hepatitis C infection,
Because universal access to prevention, diagnosis, care and treatment is a human right and promoting access to and affordability of these services is the responsibility of all stakeholders,
The participants of the inaugural World Hepatitis Summit believe it is possible and essential to set as a goal the elimination of both hepatitis B and C as public health concerns. We therefore call upon governments in all jurisdictions to develop and implement comprehensive, funded national hepatitis plans and programmes in partnership with all stakeholders and in line with the World Health Assembly Resolution 67.6 and, in collaboration with the World Health Organization, to define and agree on realistic yet aspirational global targets for prevention, testing, diagnosis, care and treatment.
With the next World Hepatitis Summit scheduled to take place from 1 to 3 November 2017, it will be critical once again to bring together a wide range of stakeholders to accelerate action toward elimination. The World Hepatitis Alliance asked Hepatology, Medicine and Policy to commission this roundtable discussion article in order to encourage reflection on how the 2015 Summit was significant for stakeholders’ efforts and why it is important to keep the momentum going ahead of the World Hepatitis Summit 2017. We are grateful to the diverse group of World Hepatitis Summit 2015 delegates who responded to the Alliance’s invitation to write roundtable contributions.
Stefan Wiktor, Team Lead, Global Hepatitis Programme, World Health Organization
The World Hepatitis Summit in 2015 was the inaugural gathering of over 500 stakeholders. Key representatives, including policy-makers, patient groups, civil society, funders, public health specialists and others, contributed to the global hepatitis discourse during the broad array of sessions offered. By bringing together these diverse groups, the Summit was able to promote collaboration in the efforts to combat viral hepatitis—an approach that is aligned with WHO’s aim to achieve equitable and accessible hepatitis services for all. In particular, patient involvement helped to define the scope of the Summit and was seen as crucial to its success.
Importantly, the Summit proved to be an ideal venue for the release of the Glasgow Declaration on Viral Hepatitis which initiated a momentum amongst patients and WHO Member States, which was strengthened by the extensive stakeholder consultations around WHO’s Global Health Sector Strategy on Viral Hepatitis (GHSS). The GHSS, which was adopted at the World Health Assembly in May 2016, supports this overall vision and outlines a set of targets and strategic priorities to meet the goal.
The Glasgow meeting also provided an opportunity for WHO to showcase and enable the implementation of the normative guidance and technical assistance offered by different teams and departments within WHO Headquarters and the Regional Offices. As the theme of the Summit was “National Planning for Viral Hepatitis,” the Summit directly supported the World Health Assembly resolution 67.6, which calls on WHO “to provide the necessary technical support to enable Member States to develop robust national viral hepatitis prevention, diagnosis and treatment strategies.”
The Summit was successful in raising the visibility of viral hepatitis and increasing awareness among Member State policy-makers of the importance of a comprehensive response. It also served as an effective learning forum, providing many of the tools necessary for national planning for viral hepatitis.
Jose Antonio Oñate Moreno, Director, Fundación Hepatos Aión, AC
Humanity is facing a great challenge, which can be solved effectively only through global collaboration: the control and elimination of viral hepatitis, particularly hepatitis B and C. Nowhere has the urgency of this challenge been highlighted so clearly as at the first World Hepatitis Summit. For patients and policy-makers alike, this event underscored the need for immediate, and united, action to confront and slow the spread of viral hepatitis.
The involvement of patient organizations demonstrated the important consideration that the medical community needs to give to hepatitis patients—those whose lives have been greatly transformed by their experiences living with the virus. The Summit provided these organizations an opportunity to speak on behalf of those who too frequently have been left out of crucial hepatitis conversations and who are now vital partners in helping create plans for effective prevention, treatment and care.
A number of Latin American patient organizations were in attendance and benefited from networking and exchanging ideas with other WHA member organizations. Topics were wide-ranging, from local and regional strategies and best practices, to ways of partnering on initiatives. They also consolidated their work through their regional network, Hepared Latinoamerica. Those of us from Mexico, where hepatitis takes the lives of over 11,000 people annually, agreed to strengthen collaboration with local and regional health authorities to implement a national strategy in 2016 to address viral hepatitis. We also resolved to ensure that patients have access to affordable direct-acting antivirals for hepatitis C. The benefits of attending the conference have become even more apparent to us in the past year.
United by a common goal, all participants at the Summit benefited from the unique and very potent opportunity to interact with others in attendance. The participation of patient organizations, representing the interests of those most directly affected by viral hepatitis, was instrumental in making their experiences and needs known. Their contributions to the global discussion are vital to helping eventually eliminate hepatitis B and C. Ongoing partnerships among health authorities, medical societies and civil service and patient organizations at a local level will help ensure global success in efforts to benefit all patients worldwide.
The inaugural World Hepatitis Summit, a three day public event jointly convened by the World Health Organization (WHO) and the World Hepatitis Alliance (WHA) and hosted by the Scottish Government and supported by Glasgow Caledonian University and Health Protection Scotland, was a significant event for the hepatitis community. A one of its kind meeting which took place in Glasgow in September 2015, the Summit brought together civil society, patients, public health specialists, policy-makers, and other key stakeholders and provided a collaborative forum to advance the viral hepatitis agenda. Given the success of this initiative it was decided that the Summit will be run every two years by WHA and WHO in collaboration with a different government each time (the next World Hepatitis Summit is scheduled to take place from 1-3 November 2017 in Sao Paulo). In the light of the newly adopted first-ever Global Health Sector Strategy on viral hepatitis, which sets a goal of eliminating these diseases by 2030, and having in mind that to deliver elimination a coordinated effort is needed, we concluded the World Hepatitis Summit is key to accelerate action towards that goal.
There were no financial contributions that supported the development of this article.
Availability of data and materials
CG provided the background piece on the World Hepatitis Summit. SW wrote the text around world delegates initiating a global response to hepatitis, providing a WHO perspective on the matter. DG and SH co-wrote the session on the importance of a coordinated effort between patients and policy-makers to eliminate viral hepatitis. AO provided the patient perspective piece, focusing on the impact of the Summit on Latin America. RP provided the last piece of the paper entitled “The beginning of the end of viral hepatitis”. All authors read and approved the final manuscript.
The authors declare that they have no competing interests. All authors attended the World Hepatitis Summit 2015. They have provided summaries of their key take-aways from the sessions. All authors approved the manuscript.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.